RxDoctor Payments Data

Bryan Mejia, MD

Internal Medicine · San Angelo, TXNPI 1114107828

Payments from drug & device makers

$2,471in general payments, 2019–2025

Across 161 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$830
  • Novo Nordisk$417
  • Amgen$232
  • Johnson & Johnson$201
  • Merck$173
  • Astellas Pharma US Inc$94
  • plus $525 from 17 others

What the payments were for

  • Food & beverage$2,39897%
  • Education$733%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,471 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$96,938
Medicare patients
216
Services billed
3,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide71$119,809
JardianceEmpagliflozin39$63,692
Tresiba Flextouch U-200Insulin Degludec33$42,853
EliquisApixaban32$37,297
OzempicSemaglutide22$37,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$36,539
JanuviaSitagliptin Phosphate19$17,924
GlyxambiEmpagliflozin/Linagliptin11$10,767
Humalog Kwikpen U-100Insulin Lispro15$9,103
VascepaIcosapent Ethyl11$8,894
Spiriva RespimatTiotropium Bromide15$7,934
PremarinEstrogens, Conjugated12$6,442
Levothyroxine Sodium269$3,085
Metoprolol Succinate158$2,676
SynthroidLevothyroxine Sodium42$2,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$75$119,80971 claims
Boehringer IngelheimJardiance, Glyxambi, Spiriva Respimat$72$82,39365 claims
Novo NordiskOzempic$417$37,08022 claims
GSKTrelegy Ellipta$14$36,53954 claims
MerckJanuvia$173$17,92419 claims
AbbVieSynthroid$830$2,41142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →